2 results
Approved WMOCompleted
To compare the efficacy of two dose levels of erlotinib (150 mg and 300 mg) on progression-free survival (PFS) in current smokers with stage IIIB/IV NSCLC after failure of first-line platinum-based chemotherapy.
Not approvedWill not start
This research proposal tests the hypothesis that an early asthma diagnosis is possible by using non-invasive biomarkers of oxidative stress/airway inflammation in exhaled air, venous blood and assessments of lung function (airway resistance by means…